Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763611 | 1.00 | CYP11B2 (0.47) | CYP11B2EP300MCHR1KCNH2KMT2A | |
| SCHEMBL16763370 | 0.92 | CYP11B2 (0.43) | CYP11B2EP300MCHR1KCNH2KMT2A | |
| SCHEMBL15415872 | 0.84 | PDE10A (0.44) | CYP11B2EP300MCHR1KCNH2CCR3 | |
| SCHEMBL19470928 | 0.83 | CYP11B2 (0.49) | CYP11B2EP300MCHR1KCNH2CCR3 | |
| SCHEMBL19470927 | 0.83 | CYP11B2 (0.49) | CYP11B2EP300MCHR1KCNH2CCR3 | |
| SCHEMBL24165560 | 0.83 | CYP11B2 (0.46) | CYP11B2MCHR1KCNH2KMT2ACCR3 | |
| SCHEMBL18807889 | 0.82 | CYP11B2 (0.43) | CYP11B2MCHR1KCNH2HDAC6TBXA2R | |
| SCHEMBL22495117 | 0.81 | FPR2 (0.47) | CYP11B2EP300HDAC6TBXA2RFPR2 | |
| SCHEMBL15416560 | 0.81 | CYP11B2 (0.41) | CYP11B2MCHR1KCNH2KMT2ATBXA2R | |
| SCHEMBL15415417 | 0.79 | CYP11B2 (0.40) | CYP11B2MCHR1KCNH2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2872502-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | CYP11B2 526/4885EP300 2562/4885MCHR1 1636/4885 |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | CYP11B2 526/4885EP300 2562/4885MCHR1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.